OCTP vs. NFX, PYC, OVB, FAB, APTA, EVG, IXI, VAL, BSFA, and BNR
Should you be buying Oxford Cannabinoid Technologies stock or one of its competitors? The main competitors of Oxford Cannabinoid Technologies include Nuformix (NFX), Physiomics (PYC), Ovoca Bio (OVB), Fusion Antibodies (FAB), Aptamer Group (APTA), Evgen Pharma (EVG), IXICO (IXI), ValiRx (VAL), BSF Enterprise (BSFA), and Burning Rock Biotech (BNR). These companies are all part of the "medical" sector.
Nuformix (LON:NFX) and Oxford Cannabinoid Technologies (LON:OCTP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.
Nuformix has higher revenue and earnings than Oxford Cannabinoid Technologies.
Nuformix received 68 more outperform votes than Oxford Cannabinoid Technologies when rated by MarketBeat users.
Nuformix has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Oxford Cannabinoid Technologies has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
Oxford Cannabinoid Technologies' return on equity of -27.25% beat Nuformix's return on equity.
In the previous week, Oxford Cannabinoid Technologies had 3 more articles in the media than Nuformix. MarketBeat recorded 3 mentions for Oxford Cannabinoid Technologies and 0 mentions for Nuformix. Oxford Cannabinoid Technologies' average media sentiment score of 0.00 beat Nuformix's score of -0.14 indicating that Nuformix is being referred to more favorably in the media.
0.2% of Nuformix shares are held by institutional investors. Comparatively, 14.1% of Oxford Cannabinoid Technologies shares are held by institutional investors. 15.0% of Nuformix shares are held by company insiders. Comparatively, 29.8% of Oxford Cannabinoid Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Nuformix beats Oxford Cannabinoid Technologies on 7 of the 11 factors compared between the two stocks.
Get Oxford Cannabinoid Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCTP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford Cannabinoid Technologies Competitors List
Related Companies and Tools
